- ReNeuron Group said that positive long-term clinical trial data for a stroke disability treatment was accepted for a podium presentation yesterday at the American Heart Association International Stroke Conference in Los Angeles.

The company recently announced positive top-line long-term data from the clinical trial in which response rates in key measures reported at three months after treatment were sustained at 12 months post-treatment.

Story provided by